Juncell Therapeutics Re-files IPO Application with HKEX, Backed by CITIC Securities

Guan Dian Network:June 16, Shanghai JuncellBio-PharmaJuncell Therapeutics Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with the sole sponsor beingCITIC Securities。

According to public information, Juncell Therapeutics is a biotechnology company dedicated to the development of innovative cell therapies and novel drugs for solid tumors. As of the filing date, the company has completed multiple rounds of financing totaling nearly RMB 800 million, with a post-money valuation of RMB 2.137 billion after its latest funding round.

On December 10, 2025, Juncell Therapeutics submitted its initial listing application to the Hong Kong Stock Exchange, officially commencing its IPO process on the Hong Kong stock market.

During the track record period, Juncell Therapeutics was not profitable and incurred net losses. For 2023, 2024, and the nine months ended September 30, 2024 and 2025, the Company’s net losses were RMB105 million, RMB212 million, RMB164 million, and RMB135 million, respectively, with the vast majority of these net losses attributable to research and development expenses and administrative expenditures.

Disclaimer: The content and data in this article are compiled by Guandian based on public information and do not constitute investment advice. Please verify before use.